Retatrutide: 71 Pounds Lost on Average — What This Means

Retatrutide made headlines when Phase 2 trial data showed an average of 71 pounds lost among participants on the highest dose — a result that sent shockwaves through the obesity medicine community. Published by Jastreboff et al. in the New England Journal of Medicine (2023), these findings showed that Eli Lilly's investigational triple-agonist drug produced weight loss approaching what was previously only possible through bariatric surgery. But what does this 71-pound figure actually mean, and how should patients interpret it?

Breaking Down the 71-Pound Figure

The 71-pound average comes from applying the 24.2% average body weight reduction seen at the 12 mg dose to the mean baseline body weight of trial participants, which was approximately 295 pounds (134 kg). Simple math: 295 x 0.242 = approximately 71 pounds.

But averages only tell part of the story. Understanding the full distribution of results reveals an even more striking picture.

These numbers are remarkable. Virtually every participant on the highest dose lost meaningful weight. More than half lost at least a quarter of their body weight. And more than a quarter of participants lost 30% or more — results that compete directly with gastric sleeve surgery.

Putting 71 Pounds in Context

To appreciate how significant this result is, consider where it falls in the landscape of weight loss interventions:

Retatrutide produced more weight loss in 48 weeks than semaglutide produces in 68 weeks. And critically, the retatrutide weight loss curve was still descending at week 48. Phase 3 trials, which run for 72+ weeks, may show even greater total weight loss.

Why Retatrutide Produces More Weight Loss

The 71-pound average is not a fluke — it reflects a fundamentally different pharmacological approach. As a triple agonist, retatrutide targets three hormone receptors simultaneously:

• GLP-1 receptors: Reduce appetite, slow gastric emptying, improve insulin secretion. This is what semaglutide does alone.
• GIP receptors: Enhance insulin sensitivity, improve fat metabolism. Combined with GLP-1, this is what tirzepatide does.
• Glucagon receptors: Increase energy expenditure, promote fat breakdown, reduce liver fat. This is the additional mechanism that retatrutide adds.

The glucagon component is the differentiator. While GLP-1 and GIP primarily reduce caloric intake by suppressing appetite, glucagon increases caloric output by boosting thermogenesis and fat oxidation. Retatrutide attacks obesity from both sides of the energy balance equation: less energy in, more energy out.

The Dose-Response Relationship

Not every participant received the 12 mg dose. The Phase 2 trial tested multiple dose levels, and the weight loss was clearly dose-dependent:

• 1 mg dose: 8.7% average weight loss (~26 lbs)
• 4 mg dose: 17.1% average weight loss (~50 lbs)
• 8 mg dose: 22.8% average weight loss (~67 lbs)
• 12 mg dose: 24.2% average weight loss (~71 lbs)

Even at the 4 mg dose, retatrutide matched semaglutide's peak efficacy. At 8 mg, it matched tirzepatide. The 12 mg dose pushed beyond anything else on the market. This dose-response gradient also provides clinical flexibility — physicians can titrate to balance efficacy with tolerability for each patient.

Beyond the Scale: What 71 Pounds Means for Health

Losing 71 pounds is not just about the number on the scale. For a person starting at 295 pounds, losing 24% of body weight translates to profound health improvements:

• Type 2 diabetes risk: Studies show that 15%+ weight loss can put type 2 diabetes into remission. At 24%, retatrutide far exceeds this threshold.
• Cardiovascular risk: Blood pressure, cholesterol, and triglyceride improvements track closely with percentage of weight lost. The Phase 2 trial showed significant improvements in all cardiovascular markers.
• Liver health: Retatrutide showed up to 86% reduction in liver fat content — directly relevant for the estimated 100 million Americans with fatty liver disease.
• Joint health: Every pound lost removes approximately 4 pounds of pressure from the knees. Losing 71 pounds means roughly 284 fewer pounds of pressure with every step.
• Sleep apnea: Weight loss of 10-15% often resolves obstructive sleep apnea. At 24%, many patients could eliminate the need for CPAP machines.

Important Caveats About the 71-Pound Number

While the results are exciting, context matters. Here are important considerations:

• Phase 2 data: The trial had 338 participants — much smaller than the thousands enrolled in Phase 3. Larger trials may show somewhat different averages.
• Clinical trial conditions: Participants received regular monitoring, dietary counseling, and support that may not reflect real-world conditions.
• Individual variation: "Average" means some people lost more and some lost less. There is no guarantee any individual will lose exactly 71 pounds.
• Starting weight matters: If you start at 200 pounds instead of 295, a 24% loss would be approximately 48 pounds. The percentage is more consistent; the absolute pounds depend on where you start.
• Not yet available: Retatrutide is still in Phase 3 trials and not FDA-approved. Approval is expected but not guaranteed.

What You Can Do Now

While retatrutide's 71-pound average is extraordinary, the weight loss medications available today are already producing life-changing results. Semaglutide and tirzepatide are FDA-approved, clinically proven, and accessible right now:

• Compounded semaglutide: Starting at $125/month, with average weight loss of 15-17%
• Compounded tirzepatide: Starting at $125/month, with average weight loss of 20-22%

Tirzepatide in particular already produces remarkable results. As a dual agonist targeting GLP-1 and GIP, it shares two of retatrutide's three mechanisms. For patients who respond well to tirzepatide, adding retatrutide when it becomes available could represent a natural progression. Learn more about how these medications work.